AI Article Synopsis
- By 2030, drug labels will be interactive and stored in the cloud, offering personalized dosing recommendations based on an individual’s genomic and physiological data.
- Precision medicine has significantly improved treatment customization, backed by innovative noninvasive technologies like smart wearables that monitor physiological health and drug levels continuously.
- Despite these advancements and promising tools for precision dosing, the integration into standard clinical practice had not been achieved by 2020 due to various challenges.
Article Abstract
Imagine it is 2030, and the drug label is in the cloud, is interactive, and can provide model-informed precision dosing support based on an individual's genomic and physiologic makeup that is uploaded via a user-friendly interface. Precision medicine has vastly improved our ability to provide tailored therapeutics, and groundbreaking advances in noninvasive systems have generated smart wearable devices that can follow our physiologic state and drug exposure in real time. One device consists of a microfluidic drug biosensor with a transmitter attached to the skin and a mobile app that displays concentration values and trends while issuing alerts and providing suggestions on dose changes when out of range. This sounds compelling, but why has model-informed precision dosing not yet become common clinical reality in 2020?
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cpt.1679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer.
Front Immunol
December 2024
Department of Pediatric Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related deaths, with conventional treatments offering limited effectiveness in advanced stages, due to distant metastases and treatment resistance. Recent advancements in immunotherapy, specifically immune checkpoint inhibitors (ICIs), have shown promise, but their efficacy as standalone therapies are often insufficient. This has led to increased interest in combining ICIs with radiotherapy, known as radioimmunotherapy (iRT), to enhance treatment outcomes.
View Article and Find Full Text PDFDose Optimization of Vancomycin in Pediatric Post-Cardiac Surgery Patients: A Population Pharmacokinetic Modeling Study.
Clin Pharmacokinet
December 2024
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background And Objective: Vancomycin is a glycopeptide antibiotic used for the treatment of severe gram-positive infections. Despite decades of clinical experience, optimized dosing for vancomycin in pediatric populations still warrants further investigation. Patients admitted to the pediatric intensive care unit (PICU) after cardiac surgery are often treated with vancomycin in case of (suspected) infection.
View Article and Find Full Text PDFAdvanced transdermal drug delivery system: A comprehensive review of microneedle technologies, novel designs, diverse applications, and critical challenges.
Int J Pharm
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
Transdermal drug delivery presents numerous advantages over conventional administration routes, including non-invasiveness, enhanced patient adherence, circumvention of hepatic first-pass metabolism, self-administration capabilities, controlled release, and increased bioavailability. Nevertheless, the barrier function of stratum corneum limits this strategy to molecules possessing requisite physicochemical attributes. To expand the field of transdermal delivery, researchers have pioneered physical enhancement techniques, with micron-sized needles emerging as a particularly promising platform for the transdermal and intradermal delivery of therapeutic agents across a spectrum of molecular sizes.
View Article and Find Full Text PDFIndividualized Antimicrobial Therapy using Antibiotic Combination Testing and Therapeutic Drug Monitoring to Treat Carbapenem-Resistant Acinetobacter baumannii Infection.
Int J Antimicrob Agents
December 2024
Department of Pharmacy, Singapore General Hospital, Singapore; Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore; Singhealth Duke-NUS Medicine Academic Clinical Programme, Singapore. Electronic address:
Article Synopsis
- - Treatment of multidrug resistant infections is tough because there aren't many effective antibiotics available, prompting the use of specialized strategies by pharmacists.
- - A two-part approach is used: in vitro antibiotic combination testing and therapeutic drug monitoring to tailor treatment, similar to precision medicine.
- - This method showed promising results in two patients with hard-to-treat Acinetobacter baumannii infections, using higher-than-recommended doses without causing any negative side effects.
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and Tc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization Y PET/CT.
Radiol Med
December 2024
Department of Radiology, IRCCS Ospedale San Raffaele, Milan, Italy.
Purpose: Personalized treatment schemes are being systematically applied to ensure best treatment outcome in oncologic patients. This is true also for personalized dosimetry in transarterial radioembolization (TARE) in hepatocellular carcinoma (HCC) patients. Precise and detailed volumetric and functional data derived from radiological and nuclear imaging methods are essential for personalized dosimetry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!